Summary of clients’ characteristics by injectable opioid agonist treatment program, with national-level tallies
| Program | Total no. of client starts; scan | No. of active clients;* scan | No. on wait list; scan | Age, yr, mean (range) | No. of clients; scan; gender | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | |||||||||||||
| Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | Scan 1 (Sept. 2018) | Scan 2 (Mar. 2019) | F | M | T† | F | M | T† | |
| A–D: All PHS programs‡§ | 286 | 312 | 67 | 119 | 0 | 112 | ‡ | ‡ | ‡ | ‡ | ‡ | ‡ | ‡ | ‡ |
| tHDM | – | 60 | ||||||||||||
| E: St. Paul’s Hospital‡ | ‡ | ‡ | 8 | 8 | 0 | 0 | ‡ | ‡ | 2 | 6 | 0 | 2 | 6 | 0 |
| F: Crosstown Clinic | 259 | 291 | 126 | 125 | 345 | 400 | 44 (21–69) | 44 (21–69) | 31 | 94 | 1 | 39 | 85 | 1 |
| DAM | 106 | 107 | ||||||||||||
| G: Vancouver Native Health Clinic | 10 | – | 1 | – | 0 | – | 53 (53) | – | 0 | 1 | 0 | – | – | – |
| H: Downtown Community Health Centre | 7 | 18 | 4 | 11 | 0 | 0 | 51 (36–68) | 48 (36–68) | 1 | 3 | 0 | 4 | 7 | 0 |
| I: Lookout iOAT Clinic | 37 | 77 | 22 | 18 | 0 | 0 | 45 (30–61) | 44 (27–62) | 4 | 18 | 0 | 4 | 14 | 0 |
| J–L: All Ottawa Inner City Health programs‡ | 26 | 29 | 22 | 22 | ≥ 55 | ≥ 75 | 40 (25–57) | 43 (25–57) | 11 | 11 | 0 | 12 | 10 | 0 |
| M: Sheldon M. Chumir Health Centre | – | 45 | – | 22 | – | 0 | – | 35 (22–48) | – | – | – | 4 | 18 | 0 |
| N: Royal Alexandra Hospital | – | 9 | – | 6 | – | 0 | – | 44 (29–64) | – | – | – | 3 | 3 | 0 |
| National-level tallies | 625 | 781 | 250 | 331 | ≥ 400 | ≥ 587 | 47 (21–69) | 43 (21–69) | 49 | 133 | 1 | 68 | 143 | 1 |
Note: DAM = diacetylmorphine, F= female, iOAT = injectable opioid agonist treatment, M = male, T = transgender or nonbinary, tHDM = tablet hydromorphone.
↵* Clients receiving at least 1 dose of iOAT in the 7 days before the scan reference date. All numbers represent clients receiving liquid hydromorphone except where programs provided DAM or tHDM (tablet iOAT) in addition to liquid hydromorphone; in these cases, the number of active clients receiving DAM and tHDM is reported underneath the total number of active clients, to indicate the size of these specific client groups.
↵† There was variable reporting for this gender category across sites.
↵‡ Data not available or data stratified by program not available where more than 1 program was operated by a single organization.
↵§ Age and gender data available only at follow-up for the 312 client starts: mean age 41 (20–73) yr, 230 men (74%), 77 women (25%), 5 transgender or nonbinary people (2%).